ArticleBritish journal of cancer2018

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Michael L Maitland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.